Press Releases

SAN FRANCISCO --(BUSINESS WIRE)--Mar. 14, 2024-- Better Therapeutics, Inc. (NASDAQ: BTTX) (the “Company”) announced today that the Company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the Company.

One million prescriptions for AspyreRx will be offered to patients in underserved communities disproportionately affected by type 2 diabetes SAN FRANCISCO --(BUSINESS WIRE)--Mar. 5, 2024-- Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for

Company to host sponsored education session on Saturday, March 09, 2024 ; Expanding access to a high quality and effective lifestyle modification intervention SAN FRANCISCO --(BUSINESS WIRE)--Mar. 4, 2024-- Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital

Signifies the FDA’s recognition of the Company’s novel Cognitive Behavioral Therapy as a potential treatment for metabolic dysfunction-associated steatohepatitis Opens an accelerated path towards a potential second indication SAN FRANCISCO --(BUSINESS WIRE)--Feb.

Agreement is an important step towards securing broad coverage SAN FRANCISCO --(BUSINESS WIRE)--Feb. 6, 2024-- Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced that it has entered into a

Over a lifetime horizon   AspyreRx plus standard of care (SoC) was estimated to be superior to SoC alone providing more life years and improvements in quality of life at a lower cost Study suggests that using AspyreRx can empower patients to better manage their diabetes, with the potential to

SAN FRANCISCO & PALO ALTO, Calif. --(BUSINESS WIRE)--Jan. 3, 2024-- Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, and Glooko, Inc. , a global leader in chronic condition management, today announced a

SAN FRANCISCO --(BUSINESS WIRE)--Jan. 2, 2024-- Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has submitted a request to the U.S. Food and Drug Administration (FDA) for Breakthrough

Savings Expected to Extend Cash Runway Sufficiently to Demonstrate Commercial Traction with AspyreRx in Type 2 Diabetes SAN FRANCISCO --(BUSINESS WIRE)--Nov. 28, 2023-- Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat

Better Therapeutics is recognized for its novel cognitive behavioral therapy app, AspyreRx™, leading the way in the North American diabetes digital behavioral therapeutics industry SAN FRANCISCO --(BUSINESS WIRE)--Nov. 14, 2023-- Better Therapeutics, Inc .